Axil Capital Partners

Developer of radiopharmaceuticals intended to offer treatment of cancer. The company engages in the research and development of therapeutic and diagnostic drugs for cancer using 64Cu which is a radioisotope of copper, enabling doctors to provide cancer treatments to the patients.

MabGenesis Inc. is a biopharmaceutical company founded in 2019 and based in Yokohama, Japan, focused on developing therapeutic monoclonal antibody drugs for both humans and animals. The company specializes in the discovery and isolation of fully human and canine/feline therapeutic antibodies, leveraging its proprietary antibody library technology. By providing novel antibody therapeutics, MabGenesis aims to alleviate symptoms and enhance the quality of life for individuals and their companion animals suffering from various diseases. The company's innovative approach offers valuable drug development opportunities for the healthcare and pharmaceutical industries.

Hirosaki Lifescience Innovation is engaged in the development, manufacture, and sale of regenerative medicine products.

GEXVal Inc. is a drug discovery company based in Fujisawa, Japan, founded in 2018. The company focuses on the research and development of innovative treatments for rare and incurable diseases, particularly in the fields of psychiatry, neurology, and pulmonary arterial hypertension. GEXVal is dedicated to addressing the needs of patients and families affected by these conditions by providing cost-effective treatment options that aim to enhance health and improve quality of life. Through its specialized research efforts, GEXVal seeks to develop compounds that target intractable diseases, enabling physicians to offer better therapeutic solutions to their patients.

Cranebio is a developer of innovative medical testing systems that focus on creating accessible and sensitive testing solutions. The company specializes in several key products, including a wearable health care kit, a device-free genetic test kit, and a rapid environmental test kit. With an emphasis on women's health, Cranebio's offerings include viral and bacterial gene testing kits, as well as wearable kits designed to monitor hormones and other health conditions. These products are designed to simplify the testing process, eliminating the need for traditional blood and urine samples, thereby making health monitoring more convenient for users.

Cellusion Inc. is a regenerative medicine company based in Tokyo, Japan, established in 2015. It focuses on research, development, manufacturing, and sales of induced pluripotent stem cell-derived corneal endothelial cells specifically for the treatment of bullous keratopathy. The company has developed a mass culture system for these cells, allowing for transplantation procedures that can significantly improve vision in affected patients. By using corneal endothelial cell substitutes derived from iPS cells, Cellusion provides a novel therapeutic solution that involves injecting the cells and replacing damaged corneal tissue, which is then manually sutured. This innovative approach aims to address the needs of patients suffering from this eye condition effectively.

AIBIOS is a biotechnology company focused on developing innovative small molecules that modulate both the innate and adaptive immune systems. Their work addresses therapeutic needs in gastroenterology, respiratory, and neurological diseases. The company has created a transporter assay platform designed to detect harmful ligands that trigger immuno-inflammatory symptoms and conditions. AIBIOS also profiles natural killer cells using specific monoclonal antibodies to analyze and diagnose immune disorders. By integrating real-world data into their research approach, AIBIOS aims to provide medical professionals with effective treatments for digestive disorders stemming from gastrointestinal issues.

Suono Bio, Inc. is a biotechnology company based in Medford, Massachusetts, that focuses on designing and developing innovative therapeutic products with a unique delivery technology. Established in 2016, the company specializes in enabling ultra-rapid, localized delivery of small molecules, biologics, nucleic acids, and gene therapies directly to the gastrointestinal tract without the need for encapsulation. Suono Bio aims to transform the treatment landscape for difficult-to-treat diseases, particularly those mediated by inflammatory processes, by facilitating effective therapy delivery that enhances patient recovery from gastrointestinal conditions.

TechsoMed is an Israeli medical device company specializing in the development of ultrasound-based real-time monitoring systems for thermal ablation procedures. These procedures have wide-ranging applications, including tumor destruction, treatment of heart arrhythmias, and blood pressure management. Despite a market size in the billions, these procedures often suffer from high failure rates due to the lack of real-time monitoring capabilities. TechsoMed's technology addresses this issue by providing physicians with the ability to monitor tissue destruction in real time, thereby enhancing the effectiveness of these minimally invasive and cost-effective treatments for patients, physicians, and insurance companies alike.

Jolly Good Inc., headquartered in Japan, specializes in developing virtual reality (VR) mobile applications tailored for television and film professionals. Their flagship product, GuruVR, offers immersive 360° content. Additionally, they provide consulting and planning services related to VR technology. Notably, Jolly Good has expanded its focus to incorporate medical and industrial applications of VR, creating high-precision AR and VR systems for medical training, long-term care training, and social skill development, aiming to optimize treatments and outcomes in the healthcare sector.

United Immunity, Co., Ltd. is a research and development company based in Tsu, Japan, specializing in the manufacture and sales of pharmaceuticals with a primary focus on cancer immunotherapy. Founded in November 2017, the company develops innovative nanoparticles and lipid nanoparticles aimed at targeting myeloid cells to treat cancer and infectious diseases. United Immunity's technology enables the delivery of various therapeutic agents directly to macrophages and dendritic cells, facilitating the development of treatments for a range of conditions, including cancer, autoimmune diseases, fibrosis, and infectious diseases.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery. Established in 2001, it specializes in antibody discovery, engineering, and research support activities. The company engages in target discovery and functional protein expression, offering services such as mouse hybridoma sequencing, recombinant protein production, and contract research for antibodies. Additionally, Perseus Proteomics develops, manufactures, and supplies a range of antibody products. By leveraging advanced antibody technology, the company aims to create innovative medicines that address the needs of patients worldwide seeking improved medical care.

LUCA Science Inc. is a biotechnology company based in Japan that specializes in developing innovative mitochondrial therapies aimed at restoring cellular bioenergetics in damaged tissues and organs. Utilizing patented iMIT technology, the company creates a novel platform of highly functional mitochondria, which can be supplied to affected areas to enhance bioenergetics and restore normal cellular functions. By harnessing mitochondria as biopharmaceutical agents, LUCA Science aims to address a range of unmet medical needs and improve disease states through the stabilization and control of mitochondrial activity. This groundbreaking approach positions LUCA Science at the forefront of mitochondrial therapy, with the potential to significantly impact the treatment landscape for various health conditions.

Jolly Good Inc., headquartered in Japan, specializes in developing virtual reality (VR) mobile applications tailored for television and film professionals. Their flagship product, GuruVR, offers immersive 360° content. Additionally, they provide consulting and planning services related to VR technology. Notably, Jolly Good has expanded its focus to incorporate medical and industrial applications of VR, creating high-precision AR and VR systems for medical training, long-term care training, and social skill development, aiming to optimize treatments and outcomes in the healthcare sector.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

United Immunity, Co., Ltd. is a research and development company based in Tsu, Japan, specializing in the manufacture and sales of pharmaceuticals with a primary focus on cancer immunotherapy. Founded in November 2017, the company develops innovative nanoparticles and lipid nanoparticles aimed at targeting myeloid cells to treat cancer and infectious diseases. United Immunity's technology enables the delivery of various therapeutic agents directly to macrophages and dendritic cells, facilitating the development of treatments for a range of conditions, including cancer, autoimmune diseases, fibrosis, and infectious diseases.

TechsoMed is an Israeli medical device company specializing in the development of ultrasound-based real-time monitoring systems for thermal ablation procedures. These procedures have wide-ranging applications, including tumor destruction, treatment of heart arrhythmias, and blood pressure management. Despite a market size in the billions, these procedures often suffer from high failure rates due to the lack of real-time monitoring capabilities. TechsoMed's technology addresses this issue by providing physicians with the ability to monitor tissue destruction in real time, thereby enhancing the effectiveness of these minimally invasive and cost-effective treatments for patients, physicians, and insurance companies alike.

Himuka AM Pharma Corp. is a pharmaceutical company based in Miyazaki City, Japan, established in February 2017. The company focuses on the research, development, and discovery of drug candidates derived from adrenomedullin, a bioactive peptide initially identified at the University of Miyazaki. Himuka AM Pharma aims to create innovative therapies that target mucosal healing and clinical remission, addressing significant unmet medical needs in healthcare. Through its specialized approach to developing adrenomedullin derivatives, the company seeks to contribute meaningfully to advancements in medical treatments.